<DOC>
	<DOCNO>NCT00789191</DOCNO>
	<brief_summary>This trial conduct Asia , Europe North America . This trial aim comparison effect glycemic control subject type 2 diabetes basal insulin analogue one oral anti-diabetic drug ( OAD ) versus oral anti-diabetic drug alone .</brief_summary>
	<brief_title>Effect Detemir Sitagliptin Blood Glucose Control Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosed type 2 diabetes least 6 month trial start Treatment least 1000 mg metformin per day least 3 month Insulinnaive ( shortterm insulin treatment 14 day allow ) DPP4 ( dipeptidyl peptidase4 ) inhibitor naive HbA1c ( glycosylated haemoglobin A1c ) 7.510.0 % central laboratory analysis BMI ( Body Mass Index ) lesser equal 45.0 kg/m2 Able willing take one subcutaneous injection every day Able willing perform mandatory SMPG ( self measure plasma glucose ) measurement Known suspected allergy intolerance trial product relate product Severe hypertension Treatment thiazolidinedione ( TZD ) GLP1 ( glucagonlike peptide1 ) analogues within 2 month prior trial start Cardiac disease , within last 12 month Impaired hepatic function Impaired renal function Proliferative retinopathy macular oedema require acute treatment Female childbearing potential Known suspect abuse alcohol , narcotic illicit substance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>